Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

NCT02960022 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT02960022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02960022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 22, 2016
Completion date
July 31, 2029
Enrollment
900 (estimated)
Sites
233

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer